151 related articles for article (PubMed ID: 33768575)
1. Metabolic syndrome cannot mask the changes of faecal microbiota compositions caused by primary hepatocellular carcinoma.
Ni J; Fu C; Huang R; Li Z; Li S; Cao P; Zhong K; Ge M; Gao Y
Lett Appl Microbiol; 2021 Jul; 73(1):73-80. PubMed ID: 33768575
[TBL] [Abstract][Full Text] [Related]
2. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
[TBL] [Abstract][Full Text] [Related]
3.
Chen T; Ding R; Chen X; Lu Y; Shi J; Lü Y; Tang B; Zhang W; Ye C; Yuan M; Yang Z
Bioengineered; 2021 Dec; 12(1):8233-8246. PubMed ID: 34592890
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next‑generation sequencing of the 16S rRNA gene fragment.
Salamon D; Sroka-Oleksiak A; Kapusta P; Szopa M; Mrozińska S; Ludwig-Słomczyńska AH; Wołkow PP; Bulanda M; Klupa T; Małecki MT; Gosiewski T
Pol Arch Intern Med; 2018 Jun; 128(6):336-343. PubMed ID: 29657308
[TBL] [Abstract][Full Text] [Related]
6. Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma.
Iida N; Mizukoshi E; Yamashita T; Terashima T; Arai K; Seishima J; Kaneko S
Int J Cancer; 2019 Nov; 145(10):2701-2711. PubMed ID: 30980680
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
[TBL] [Abstract][Full Text] [Related]
8. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response.
Zhang N; Gou Y; Liang S; Chen N; Liu Y; He Q; Zhang J
J Immunol Res; 2021; 2021():4973589. PubMed ID: 34722779
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals.
Sedighi M; Razavi S; Navab-Moghadam F; Khamseh ME; Alaei-Shahmiri F; Mehrtash A; Amirmozafari N
Microb Pathog; 2017 Oct; 111():362-369. PubMed ID: 28912092
[TBL] [Abstract][Full Text] [Related]
11. Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children.
Gallardo-Becerra L; Cornejo-Granados F; García-López R; Valdez-Lara A; Bikel S; Canizales-Quinteros S; López-Contreras BE; Mendoza-Vargas A; Nielsen H; Ochoa-Leyva A
Microb Cell Fact; 2020 Mar; 19(1):61. PubMed ID: 32143621
[TBL] [Abstract][Full Text] [Related]
12. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.
Piñero F; Vazquez M; Baré P; Rohr C; Mendizabal M; Sciara M; Alonso C; Fay F; Silva M
Ann Hepatol; 2019; 18(3):480-487. PubMed ID: 31023615
[TBL] [Abstract][Full Text] [Related]
13. Distinctly altered gut microbiota in the progression of liver disease.
Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
[TBL] [Abstract][Full Text] [Related]
14. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
Yang J; He Q; Lu F; Chen K; Ni Z; Wang H; Zhou C; Zhang Y; Chen B; Bo Z; Li J; Yu H; Wang Y; Chen G
Gut Microbes; 2023; 15(1):2201159. PubMed ID: 37089022
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation.
Wu YN; Zhang L; Chen T; Li X; He LH; Liu GX
World J Gastroenterol; 2020 Sep; 26(36):5420-5436. PubMed ID: 33024394
[TBL] [Abstract][Full Text] [Related]
16. An Integrated Fecal Microbiome and Metabolomics in T2DM Rats Reveal Antidiabetes Effects from Host-Microbial Metabolic Axis of EtOAc Extract from
Shao J; Liu Y; Wang H; Luo Y; Chen L
Oxid Med Cell Longev; 2020; 2020():1805418. PubMed ID: 32566075
[TBL] [Abstract][Full Text] [Related]
17. Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma.
Cho EJ; Leem S; Kim SA; Yang J; Lee YB; Kim SS; Cheong JY; Cho SW; Kim JW; Kim SM; Yoon JH; Park T
Sci Rep; 2019 May; 9(1):7536. PubMed ID: 31101866
[TBL] [Abstract][Full Text] [Related]
18. Gut microbial signatures of patients with primary hepatocellular carcinoma and their healthy first-degree relatives.
Feng J; Wu Y; Dai P; Wang D; Liu L; Chai B
J Appl Microbiol; 2023 Oct; 134(10):. PubMed ID: 37777841
[TBL] [Abstract][Full Text] [Related]
19. Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma.
Huo R; Chen Y; Li J; Xu Q; Guo J; Xu H; You Y; Zheng C; Chen Y
Curr Oncol; 2023 Feb; 30(2):1818-1830. PubMed ID: 36826102
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota Associations with Metabolic Health and Obesity Status in Older Adults.
Zhong X; Harrington JM; Millar SR; Perry IJ; O'Toole PW; Phillips CM
Nutrients; 2020 Aug; 12(8):. PubMed ID: 32784721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
